Clinical trials: Thrombin
Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
The objective of the present study is to assess blood coagulation disorders in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.
- Trial name
- NCT03195543
- Testing
- Platelet function analyzer-100, Light transmission aggregometry, Rotational thromboelastometry
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Hip Replacement, Total
Blood-saving Effect of Combined Intravenous Tranexamic Acid With Topical Floseal® Application Total Hip Arthroplasty
Total hip arthroplasty (THA) is an excellent surgical procedure for patients with end-stage hip diseases. However, THA is associated with considerable blood loss and increasing needs for allogenic blood transfusion.
- Trial name
- NCT03623789
- Testing
- intravenous application of tranexamic acid, Floseal hemostatic matrix, Normal saline
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Beta Thalassemia Major Anemia
Thrombin Generation in Beta-thalassemia Major
This study aims to evaluate the persistence of a hypercoagulable state in chronically-transfused patients with beta thalassemia major, by using the thrombin generation test (performed in whole blood and plasma).
- Trial name
- TG-THAL (NCT04962984)
- Testing
- blood sampling
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Cirrhosis
Rôle of the Soluble Endothelial Protein C Receptor in Cirrhosis-associated Hypercoagulability State (EXERCISE)
Cirrhosis is a condition in which the liver does not function properly due to long-term damage. This damage is characterized by the replacement of normal liver tissue by scar tissue.
- Trial name
- EXERCISE (NCT03625726)
- Testing
- Thrombin generation assay (in vitro)
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Healthy
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
The primary purpose of this study is to evaluate the reversal of the anticoagulant effects of milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa (rFVIIa) in healthy participants as…
- Trial name
- NCT04543383
- Testing
- Milvexian, 4-Factor Prothrombin Complex Concentrate (4F-PCC), Recombinant Human Factor VIIa (rFVIIa)
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Sickle Cell Disease, Vaso-occlusive Crisis
Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain.
- Trial name
- SCD-TGA (NCT05376046)
- Testing
- Erythrocytic parameters and thrombin generation assay measurement
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BILLOIR